

Gencurix reveals new study for early stage breast cancer

13 August 2019 | News

This is the first study that compares GenesWell™ BCT score with the Oncotype DX recurrence score (RS) for risk classification.



Gencurix, Inc., a Korea based company dedicated in development and market of innovative molecular diagnostics, has announced the publication of a new study on *Frontiers in Oncology* comparing GenesWell™ BCT, a prognostic multigene test, with Genomic Health's Oncotype DX in patients with early-stage breast cancer.

This is the first study that compares GenesWell™ BCT score with the Oncotype DX recurrence score (RS) for risk classification. A key finding from the study is that the overall concordance between the BCT score and RS was moderate but the concordance was low in women aged 50 years or younger, or with lymph node-positive breast cancer.

GenesWell BCT is a qRT-PCR-based assay developed to reflect all age groups. It measures the relative expression levels of six prognostic genes and two clinical variables (tumor size and nodal status) using FFPE tumor tissues. GenesWell BCT is a prognostic multigene assay that has been approved by Korean Ministry of Food and Drug Safety (MFDS) and its prognostic value and ability to predict chemo-benefit have been validated by a number of studies.

"The results reveals the importance of including clinical pathologic factors in predicting recurrence and deciding on whether to add chemotherapy. From the very beginning of algorithm design for GenesWell BCT, clinical pathological factors have been taken into account," said Sang-rae Cho, the CEO of Gencurix. "The findings build on prior studies that demonstrated the clinical utility of GenesWell BCT for predicting which women will benefit from adjunctive chemotherapy at diagnosis in all ages."